Greater levels of physical activity are associated with a decreased risk of mortality and cardiovascular disease events in low-, middle-, and high-income countries.
Greater levels of physical activity are associated with a decreased risk of mortality and cardiovascular disease (CVD) events in low-, middle-, and high-income countries.
In a study published in The Lancet, researchers recruited participants from 17 countries to track the physical activity of people of different ages (35 to 70 years old) with different economic backgrounds. All of the participants were analyzed through their responses to the International Physical Activity Questionnaire (IPAQ), and mortality and CVD were recorded during an average of 6.9 years follow-up. The effects of physical activity on mortality and CVD were then adjusted for certain sociodemographic factors.
“Meeting physical activity guidelines by walking for as little as 30 minutes most days of the week has a substantial benefit, and higher physical activity is associated with even lower risks,” lead author Scott Lear, PhD, professor of Simon Fraser University’s Faculty of Health Sciences and Pfizer/Heart & Stroke Foundation Chair in Cardiovascular Prevention Research at St. Paul’s Hospital in Canada, said in a statement.
A total of 130,843 participants completed the IPAQ and did not have preexisting CVD. High physical activity was associated with a significant reduction in mortality and major CVD when compared to those with low physical activity. Additionally, higher physical activity was linked specifically with a lower risk of CVD and mortality in high-, middle-, and low-income countries.
“The affordability of other cardiovascular disease interventions, such as generic drugs and consuming fruits and vegetables, are often beyond the reach of many people in low-income and middle-income countries,” Lear noted. “However, physical activity represents a low-cost approach to preventing cardiovascular disease, and our study provides robust evidence to support public health interventions to increase all forms of physical activity in these regions.”
Furthermore, the study suggested that either higher recreational or non-recreational physical activity both contribute to a lower risk of mortality and CVD events among all income levels. Increasing physical activity is a low cost and global strategy that could decrease the number of deaths and CVD events among middle-aged individuals.
“Our study found that high physical activity was only possible in people who completed physical activity as a form of transport, part of their job or through housework—with 37.9% people who acted in this way attaining this level of activity, compared to 2.9% who were only physically active in their leisure time,” Lear concluded. “This reflects the challenge of trying to be highly active during limited daily leisure time outside of work and domestic duties.”
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More